Budesonide is a synthetic corticosteroid developed to provide strong local anti-inflammatory effects with minimal systemic side effects. It is widely used in the treatment of asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. The drug was developed in the 1970s by Astra AB (later part of AstraZeneca) during efforts to create safer corticosteroids with high topical potency and rapid metabolism in the liver. Initially introduced as an inhaled therapy for asthma, budesonide later became available in nasal, oral, and rectal formulations, expanding its use in respiratory and gastrointestinal disorders. Its inclusion in combination inhalers such as Symbicort further improved long-term management of airway diseases. Today, budesonide remains an important and widely prescribed anti-inflammatory medication due to its effectiveness and improved safety profile compared to older systemic steroids.
BRAND NAMES
Pulmicort – inhaler or nebulizer for asthma
Rhinocort – nasal spray for allergic rhinitis
Entocort – oral capsules for Crohn’s disease
Uceris – oral tablets for ulcerative colitis
MECHANISM OF ACTION
Budesonide works by reducing inflammation and calming the immune system, helping relieve swelling and irritation in the lungs, nose, and intestines
PHARMACOKINETICS
Absorption
Budesonide is rapidly absorbed when taken orally or via inhalation, but it undergoes extensive first-pass metabolism in the liver, which reduces the amount that reaches the bloodstream. Inhaled and nasal forms act mainly locally, with minimal systemic absorption.
Distribution
Budesonide is widely distributed in body tissues, with a volume of distribution of about3 L/kg, and it is highly bound (≈85–90%) to plasma proteins.
Metabolism
Budesonide is primarily metabolized in the liver by CYP3A enzymes into inactive metabolites, which are then eliminated from the body.
Excretion
Budesonide is mainly excreted in the urine as inactive metabolites, with a small amount eliminated in feces.
PHARMACODYNAMICS
Budesonide reduces inflammation by binding to glucocorticoid receptors, suppressing immune responses and easing swelling and irritation.
ADMINISTRATION
Budesonide can be administered by inhalation, orally, or as a nasal spray, depending on the condition being treated.
DOSAGE AND STRENGTH
Inhalation (asthma): 180–800 µg twice daily (via inhaler or nebulizer)
Nasal spray (allergic rhinitis): 64–256 µg once or twice daily
Oral capsules/tablets (Crohn’s/ulcerative colitis): 3–9 mg daily, usually divided into 2 doses
FOOD INTERACTIONS
Budesonide has minimal food interactions, but taking oral capsules with food may slightly reduce absorption. It is generally safe to take with or without meals.
DRUG INTERACTIONS
Budesonide can interact with drugs that affect liver enzymes, especially CYP3A4 inhibitors (like ketoconazole or ritonavir), which can increase budesonide levels and risk side effects. CYP3A4 inducers (like rifampicin) can reduce its effectiveness. Other corticosteroids may add to systemic effects if used together.
CONTRAINDICATIONS
Hypersensitivity to budesonide or any corticosteroid component
Active untreated infections (bacterial, viral, fungal, or parasitic)
Systemic fungal infections
SIDE EFFECTS
Respiratory: throat irritation, cough, hoarseness, nasal dryness or bleeding
Gastrointestinal: nausea, abdominal pain
Systemic (rare with inhaled/nasal forms): headache, dizziness, adrenal suppression, slowed growth in children with long-term use
Skin: bruising, acne
OVERDOSE
Systemic corticosteroid effects: fatigue, weakness, nausea, vomiting
Hormonal disturbances: adrenal suppression, changes in blood sugar
Electrolyte imbalance in severe cases
TOXICITY
Budesonide toxicity is rare but can occur with long-term or high-dose use, leading to adrenal suppression, Cushing-like symptoms, slowed growth in children, bone loss, and increased infection risk.
